Pharmacokinetics of low-molecular-weight heparin and unfractionated heparin during elective aortobifemoral bypass grafting

Perioperative monitoring has demonstrated that administration of heparin on an empirical basis is associated with a wide variation in patient response and elimination rate. This problem may be overcome by intervention on the basis of perioperative monitoring or by using forms of heparin with differe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of vascular surgery 1991-08, Vol.14 (2), p.208-214
Hauptverfasser: Kroneman, Herman, Eikelboom, Bert C., Knot, E.A.R., de Smit, Pìet, Groenland, Theo H.N., de Maat, Moniek P.M., Van Urk, Hero
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 214
container_issue 2
container_start_page 208
container_title Journal of vascular surgery
container_volume 14
creator Kroneman, Herman
Eikelboom, Bert C.
Knot, E.A.R.
de Smit, Pìet
Groenland, Theo H.N.
de Maat, Moniek P.M.
Van Urk, Hero
description Perioperative monitoring has demonstrated that administration of heparin on an empirical basis is associated with a wide variation in patient response and elimination rate. This problem may be overcome by intervention on the basis of perioperative monitoring or by using forms of heparin with different pharmacokinetic properties. When compared with unfractionated heparin, low-molecular-weight heparin has a higher bioavailability after subcutaneous administration, a linear clearance mechanism with a prolonged half-life, and is at least as effective in preventing postoperative vein thrombosis. Theoretically these characteristics of low-molecular-weight heparin could lead to more predictable levels of heparin activity. In this study we compared the pharmacokinetics of low-molecular-weight heparin and unfractionated heparin after an intravenous injection in patients undergoing aortic graft surgery. Heparin activity was measured before heparin administration and at 5, 20, 35, 50, 65, 80, 95, and 110 minutes after administration. The anti-Xa activity in the low-molecular-weight heparin group showed less variation and was more sustained when compared to the unfractionated heparin group. Fibrin degradation products were moderately correlated with the anti-factor Xa levels of the low-molecular-weight heparin group, but no correlation was found in the unfractionated heparin group. The anti-factor Xa activity of low-molecular-weight heparin was, in contrast to that of unfractionated heparin, not completely reversible by protamine administration. The blood loss was comparable in both groups. In contrast to what was expected, the pharmacokinetic profiles of low-molecular-weight heparin and unfractionated heparin showed a similarity after intravenous injection in patients undergoing aortobifemoral bypass grafting. Factors that could have influenced the pharmacokinetic behavior of heparin are discussed. (J V ASC S URG 1991;14:208-14.)
doi_str_mv 10.1067/mva.1991.29897
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80713972</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0741521491700275</els_id><sourcerecordid>80713972</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-d1cdeef86c89ee5c30e5a8eba4392f02b42b1eeadfd3fb14842a48aaed2ce60b3</originalsourceid><addsrcrecordid>eNp1kE1v1DAQhi0EareFKzckHypuWezESexjVQGtVAkOcLYm9njXkMRb29mq_Hq83VU5cZk5vM986CHkPWdrzrr-07SHNVeKr2slVf-KrDhTfdVJpl6TFesFr9qai3NykdIvxjhvZX9GznjXMsG6FfnzfQtxAhN--xmzN4kGR8fwWE1hRLOMEKtH9JttplvcQfQzhdnSZXYRTPZhhoz2JbJLqRuKZTL7PVIIMYfBO5xChJEOTztIiW4iuFy4t-SNgzHhu1O_JD-_fP5xc1vdf_t6d3N9XxnBZK4sNxbRyc5IhdiahmELEgcQjaodqwdRDxwRrLONG7iQogYhAdDWBjs2NJfk43HvLoaHBVPWk08GxxFmDEvSkvW8UX1dwPURNDGkFNHpXfQTxCfNmT7I1kW2PsjWz7LLwIfT5mWY0P7Dj3ZLfnXKIRkYi7PZ-PSCtZx3sjnclUcMi4W9x6iT8TgbtD4Wk9oG_78P_gLJ0Z-V</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80713972</pqid></control><display><type>article</type><title>Pharmacokinetics of low-molecular-weight heparin and unfractionated heparin during elective aortobifemoral bypass grafting</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>EZB Electronic Journals Library</source><creator>Kroneman, Herman ; Eikelboom, Bert C. ; Knot, E.A.R. ; de Smit, Pìet ; Groenland, Theo H.N. ; de Maat, Moniek P.M. ; Van Urk, Hero</creator><creatorcontrib>Kroneman, Herman ; Eikelboom, Bert C. ; Knot, E.A.R. ; de Smit, Pìet ; Groenland, Theo H.N. ; de Maat, Moniek P.M. ; Van Urk, Hero</creatorcontrib><description>Perioperative monitoring has demonstrated that administration of heparin on an empirical basis is associated with a wide variation in patient response and elimination rate. This problem may be overcome by intervention on the basis of perioperative monitoring or by using forms of heparin with different pharmacokinetic properties. When compared with unfractionated heparin, low-molecular-weight heparin has a higher bioavailability after subcutaneous administration, a linear clearance mechanism with a prolonged half-life, and is at least as effective in preventing postoperative vein thrombosis. Theoretically these characteristics of low-molecular-weight heparin could lead to more predictable levels of heparin activity. In this study we compared the pharmacokinetics of low-molecular-weight heparin and unfractionated heparin after an intravenous injection in patients undergoing aortic graft surgery. Heparin activity was measured before heparin administration and at 5, 20, 35, 50, 65, 80, 95, and 110 minutes after administration. The anti-Xa activity in the low-molecular-weight heparin group showed less variation and was more sustained when compared to the unfractionated heparin group. Fibrin degradation products were moderately correlated with the anti-factor Xa levels of the low-molecular-weight heparin group, but no correlation was found in the unfractionated heparin group. The anti-factor Xa activity of low-molecular-weight heparin was, in contrast to that of unfractionated heparin, not completely reversible by protamine administration. The blood loss was comparable in both groups. In contrast to what was expected, the pharmacokinetic profiles of low-molecular-weight heparin and unfractionated heparin showed a similarity after intravenous injection in patients undergoing aortobifemoral bypass grafting. Factors that could have influenced the pharmacokinetic behavior of heparin are discussed. (J V ASC S URG 1991;14:208-14.)</description><identifier>ISSN: 0741-5214</identifier><identifier>EISSN: 1097-6809</identifier><identifier>DOI: 10.1067/mva.1991.29897</identifier><identifier>PMID: 1650406</identifier><identifier>CODEN: JVSUES</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Anesthesia ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Aorta, Abdominal - surgery ; Biological and medical sciences ; Blood Loss, Surgical ; Blood Vessel Prosthesis ; Femoral Artery - surgery ; Fibrin Fibrinogen Degradation Products - analysis ; Heparin - administration &amp; dosage ; Heparin - blood ; Heparin - pharmacokinetics ; Heparin, Low-Molecular-Weight - administration &amp; dosage ; Heparin, Low-Molecular-Weight - blood ; Heparin, Low-Molecular-Weight - pharmacokinetics ; Humans ; Injections, Intravenous ; Intraoperative Period ; Medical sciences ; Partial Thromboplastin Time ; Polyethylene Terephthalates ; Time Factors</subject><ispartof>Journal of vascular surgery, 1991-08, Vol.14 (2), p.208-214</ispartof><rights>1991 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter</rights><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-d1cdeef86c89ee5c30e5a8eba4392f02b42b1eeadfd3fb14842a48aaed2ce60b3</citedby><cites>FETCH-LOGICAL-c408t-d1cdeef86c89ee5c30e5a8eba4392f02b42b1eeadfd3fb14842a48aaed2ce60b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1067/mva.1991.29897$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=5116832$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1650406$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kroneman, Herman</creatorcontrib><creatorcontrib>Eikelboom, Bert C.</creatorcontrib><creatorcontrib>Knot, E.A.R.</creatorcontrib><creatorcontrib>de Smit, Pìet</creatorcontrib><creatorcontrib>Groenland, Theo H.N.</creatorcontrib><creatorcontrib>de Maat, Moniek P.M.</creatorcontrib><creatorcontrib>Van Urk, Hero</creatorcontrib><title>Pharmacokinetics of low-molecular-weight heparin and unfractionated heparin during elective aortobifemoral bypass grafting</title><title>Journal of vascular surgery</title><addtitle>J Vasc Surg</addtitle><description>Perioperative monitoring has demonstrated that administration of heparin on an empirical basis is associated with a wide variation in patient response and elimination rate. This problem may be overcome by intervention on the basis of perioperative monitoring or by using forms of heparin with different pharmacokinetic properties. When compared with unfractionated heparin, low-molecular-weight heparin has a higher bioavailability after subcutaneous administration, a linear clearance mechanism with a prolonged half-life, and is at least as effective in preventing postoperative vein thrombosis. Theoretically these characteristics of low-molecular-weight heparin could lead to more predictable levels of heparin activity. In this study we compared the pharmacokinetics of low-molecular-weight heparin and unfractionated heparin after an intravenous injection in patients undergoing aortic graft surgery. Heparin activity was measured before heparin administration and at 5, 20, 35, 50, 65, 80, 95, and 110 minutes after administration. The anti-Xa activity in the low-molecular-weight heparin group showed less variation and was more sustained when compared to the unfractionated heparin group. Fibrin degradation products were moderately correlated with the anti-factor Xa levels of the low-molecular-weight heparin group, but no correlation was found in the unfractionated heparin group. The anti-factor Xa activity of low-molecular-weight heparin was, in contrast to that of unfractionated heparin, not completely reversible by protamine administration. The blood loss was comparable in both groups. In contrast to what was expected, the pharmacokinetic profiles of low-molecular-weight heparin and unfractionated heparin showed a similarity after intravenous injection in patients undergoing aortobifemoral bypass grafting. Factors that could have influenced the pharmacokinetic behavior of heparin are discussed. (J V ASC S URG 1991;14:208-14.)</description><subject>Anesthesia</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Aorta, Abdominal - surgery</subject><subject>Biological and medical sciences</subject><subject>Blood Loss, Surgical</subject><subject>Blood Vessel Prosthesis</subject><subject>Femoral Artery - surgery</subject><subject>Fibrin Fibrinogen Degradation Products - analysis</subject><subject>Heparin - administration &amp; dosage</subject><subject>Heparin - blood</subject><subject>Heparin - pharmacokinetics</subject><subject>Heparin, Low-Molecular-Weight - administration &amp; dosage</subject><subject>Heparin, Low-Molecular-Weight - blood</subject><subject>Heparin, Low-Molecular-Weight - pharmacokinetics</subject><subject>Humans</subject><subject>Injections, Intravenous</subject><subject>Intraoperative Period</subject><subject>Medical sciences</subject><subject>Partial Thromboplastin Time</subject><subject>Polyethylene Terephthalates</subject><subject>Time Factors</subject><issn>0741-5214</issn><issn>1097-6809</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1v1DAQhi0EareFKzckHypuWezESexjVQGtVAkOcLYm9njXkMRb29mq_Hq83VU5cZk5vM986CHkPWdrzrr-07SHNVeKr2slVf-KrDhTfdVJpl6TFesFr9qai3NykdIvxjhvZX9GznjXMsG6FfnzfQtxAhN--xmzN4kGR8fwWE1hRLOMEKtH9JttplvcQfQzhdnSZXYRTPZhhoz2JbJLqRuKZTL7PVIIMYfBO5xChJEOTztIiW4iuFy4t-SNgzHhu1O_JD-_fP5xc1vdf_t6d3N9XxnBZK4sNxbRyc5IhdiahmELEgcQjaodqwdRDxwRrLONG7iQogYhAdDWBjs2NJfk43HvLoaHBVPWk08GxxFmDEvSkvW8UX1dwPURNDGkFNHpXfQTxCfNmT7I1kW2PsjWz7LLwIfT5mWY0P7Dj3ZLfnXKIRkYi7PZ-PSCtZx3sjnclUcMi4W9x6iT8TgbtD4Wk9oG_78P_gLJ0Z-V</recordid><startdate>19910801</startdate><enddate>19910801</enddate><creator>Kroneman, Herman</creator><creator>Eikelboom, Bert C.</creator><creator>Knot, E.A.R.</creator><creator>de Smit, Pìet</creator><creator>Groenland, Theo H.N.</creator><creator>de Maat, Moniek P.M.</creator><creator>Van Urk, Hero</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19910801</creationdate><title>Pharmacokinetics of low-molecular-weight heparin and unfractionated heparin during elective aortobifemoral bypass grafting</title><author>Kroneman, Herman ; Eikelboom, Bert C. ; Knot, E.A.R. ; de Smit, Pìet ; Groenland, Theo H.N. ; de Maat, Moniek P.M. ; Van Urk, Hero</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-d1cdeef86c89ee5c30e5a8eba4392f02b42b1eeadfd3fb14842a48aaed2ce60b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Anesthesia</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Aorta, Abdominal - surgery</topic><topic>Biological and medical sciences</topic><topic>Blood Loss, Surgical</topic><topic>Blood Vessel Prosthesis</topic><topic>Femoral Artery - surgery</topic><topic>Fibrin Fibrinogen Degradation Products - analysis</topic><topic>Heparin - administration &amp; dosage</topic><topic>Heparin - blood</topic><topic>Heparin - pharmacokinetics</topic><topic>Heparin, Low-Molecular-Weight - administration &amp; dosage</topic><topic>Heparin, Low-Molecular-Weight - blood</topic><topic>Heparin, Low-Molecular-Weight - pharmacokinetics</topic><topic>Humans</topic><topic>Injections, Intravenous</topic><topic>Intraoperative Period</topic><topic>Medical sciences</topic><topic>Partial Thromboplastin Time</topic><topic>Polyethylene Terephthalates</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kroneman, Herman</creatorcontrib><creatorcontrib>Eikelboom, Bert C.</creatorcontrib><creatorcontrib>Knot, E.A.R.</creatorcontrib><creatorcontrib>de Smit, Pìet</creatorcontrib><creatorcontrib>Groenland, Theo H.N.</creatorcontrib><creatorcontrib>de Maat, Moniek P.M.</creatorcontrib><creatorcontrib>Van Urk, Hero</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of vascular surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kroneman, Herman</au><au>Eikelboom, Bert C.</au><au>Knot, E.A.R.</au><au>de Smit, Pìet</au><au>Groenland, Theo H.N.</au><au>de Maat, Moniek P.M.</au><au>Van Urk, Hero</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacokinetics of low-molecular-weight heparin and unfractionated heparin during elective aortobifemoral bypass grafting</atitle><jtitle>Journal of vascular surgery</jtitle><addtitle>J Vasc Surg</addtitle><date>1991-08-01</date><risdate>1991</risdate><volume>14</volume><issue>2</issue><spage>208</spage><epage>214</epage><pages>208-214</pages><issn>0741-5214</issn><eissn>1097-6809</eissn><coden>JVSUES</coden><abstract>Perioperative monitoring has demonstrated that administration of heparin on an empirical basis is associated with a wide variation in patient response and elimination rate. This problem may be overcome by intervention on the basis of perioperative monitoring or by using forms of heparin with different pharmacokinetic properties. When compared with unfractionated heparin, low-molecular-weight heparin has a higher bioavailability after subcutaneous administration, a linear clearance mechanism with a prolonged half-life, and is at least as effective in preventing postoperative vein thrombosis. Theoretically these characteristics of low-molecular-weight heparin could lead to more predictable levels of heparin activity. In this study we compared the pharmacokinetics of low-molecular-weight heparin and unfractionated heparin after an intravenous injection in patients undergoing aortic graft surgery. Heparin activity was measured before heparin administration and at 5, 20, 35, 50, 65, 80, 95, and 110 minutes after administration. The anti-Xa activity in the low-molecular-weight heparin group showed less variation and was more sustained when compared to the unfractionated heparin group. Fibrin degradation products were moderately correlated with the anti-factor Xa levels of the low-molecular-weight heparin group, but no correlation was found in the unfractionated heparin group. The anti-factor Xa activity of low-molecular-weight heparin was, in contrast to that of unfractionated heparin, not completely reversible by protamine administration. The blood loss was comparable in both groups. In contrast to what was expected, the pharmacokinetic profiles of low-molecular-weight heparin and unfractionated heparin showed a similarity after intravenous injection in patients undergoing aortobifemoral bypass grafting. Factors that could have influenced the pharmacokinetic behavior of heparin are discussed. (J V ASC S URG 1991;14:208-14.)</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>1650406</pmid><doi>10.1067/mva.1991.29897</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0741-5214
ispartof Journal of vascular surgery, 1991-08, Vol.14 (2), p.208-214
issn 0741-5214
1097-6809
language eng
recordid cdi_proquest_miscellaneous_80713972
source MEDLINE; Elsevier ScienceDirect Journals Complete; EZB Electronic Journals Library
subjects Anesthesia
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Aorta, Abdominal - surgery
Biological and medical sciences
Blood Loss, Surgical
Blood Vessel Prosthesis
Femoral Artery - surgery
Fibrin Fibrinogen Degradation Products - analysis
Heparin - administration & dosage
Heparin - blood
Heparin - pharmacokinetics
Heparin, Low-Molecular-Weight - administration & dosage
Heparin, Low-Molecular-Weight - blood
Heparin, Low-Molecular-Weight - pharmacokinetics
Humans
Injections, Intravenous
Intraoperative Period
Medical sciences
Partial Thromboplastin Time
Polyethylene Terephthalates
Time Factors
title Pharmacokinetics of low-molecular-weight heparin and unfractionated heparin during elective aortobifemoral bypass grafting
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T17%3A02%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacokinetics%20of%20low-molecular-weight%20heparin%20and%20unfractionated%20heparin%20during%20elective%20aortobifemoral%20bypass%20grafting&rft.jtitle=Journal%20of%20vascular%20surgery&rft.au=Kroneman,%20Herman&rft.date=1991-08-01&rft.volume=14&rft.issue=2&rft.spage=208&rft.epage=214&rft.pages=208-214&rft.issn=0741-5214&rft.eissn=1097-6809&rft.coden=JVSUES&rft_id=info:doi/10.1067/mva.1991.29897&rft_dat=%3Cproquest_cross%3E80713972%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80713972&rft_id=info:pmid/1650406&rft_els_id=0741521491700275&rfr_iscdi=true